Melissa Rienstra, MD
Internal Medicine · Social Circle, GANPI 1407351117
Payments from drug & device makers
Across 132 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$271
- Lilly USA, LLC$264
- Novo Nordisk$234
- AstraZeneca$231
- GSK$206
- Exact Sciences$149
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,464100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $271 |
| Lilly USA, LLC | 14 | $264 |
| Novo Nordisk | 13 | $234 |
| AstraZeneca | 13 | $231 |
| GSK | 11 | $206 |
| Exact Sciences | 8 | $149 |
| Merck | 8 | $122 |
| Boehringer Ingelheim | 5 | $104 |
| Johnson & Johnson | 5 | $95 |
| Dexcom, Inc. | 4 | $91 |
| Abbott | 4 | $80 |
| Amgen | 5 | $79 |
| Bayer | 4 | $75 |
| AbbVie | 4 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Astellas Pharma US Inc | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
| Corcept Therapeutics | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Novartis | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Exeltis, USA Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$2,464 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 75 | $135,183 |
| OzempicSemaglutide | 85 | $107,645 |
| EliquisApixaban | 107 | $90,656 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $71,408 |
| TrulicityDulaglutide | 42 | $58,971 |
| RybelsusSemaglutide | 31 | $40,659 |
| XareltoRivaroxaban | 35 | $35,731 |
| JanuviaSitagliptin Phosphate | 40 | $33,158 |
| JardianceEmpagliflozin | 22 | $26,010 |
| Repatha SureclickEvolocumab | 17 | $22,752 |
| FarxigaDapagliflozin Propanediol | 18 | $19,056 |
| MyrbetriqMirabegron | 14 | $18,830 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $13,133 |
| LinzessLinaclotide | 11 | $11,064 |
| Lagevrio (Eua)Molnupiravir | 11 | $7,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $264 | $194,154117 claims |
| Novo NordiskOzempic, Rybelsus | $234 | $148,304116 claims |
| PfizerEliquis | $271 | $90,656107 claims |
| GSKTrelegy Ellipta | $206 | $71,40878 claims |
| MerckJanuvia, Lagevrio (Eua) | $122 | $40,57451 claims |
| Johnson & JohnsonXarelto | $95 | $35,73135 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $104 | $32,45935 claims |
| AstraZenecaFarxiga | $231 | $19,05618 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $18,83014 claims |
| AbbVieLinzess, Synthroid | $72 | $14,55359 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Social Circle
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.